Blockade Medical, an Irvine, California-based developer of catheter based therapeutic devices for the treatment of cerebral aneurysms and ischemic stroke, closed a round of equity financing of undisclosed amount.
Backers included existing investors and new investors TitanMed Capital and GP Healthcare Capital.
The company intends to use the funds for the continued commercialization of the Barricade Coil System™ and development of novel neurovascular devices for the treatment of aneurysms, stroke and other neurovascular conditions.
Led by Dave Ferrera, President and Chief Technology Officer, Blockade Medical is a medical device company focused on expanding the endovascular management of ischemic stroke, hemorrhagic stroke and related diseases of the neurovascular system.
The company’s Barricade Coil System is an embolization coil line, which is designed to endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.
The system, which received CE Mark in July 2012 and FDA 510(k) Clearance in March 2013, is a comprehensive bare platinum coil line available in framing, filling and finishing shapes.
The company also announced the formation of a joint venture for future manufacturing of Blockade Devices for the Chinese marketplace.